Kura Oncology to Report Fourth Quarter and Full Year 2022 Financial Results

Rhea-AI Summary

Kura Oncology, Inc. (Nasdaq: KURA) will release its fourth quarter and full year 2022 financial results on February 23, 2023, after U.S. market close. A conference call and webcast will follow at 4:30 p.m. ET to discuss the results and provide corporate updates. Kura is focused on precision medicine for cancer, with ongoing trials for its drug candidates. Ziftomenib is in a registration-directed trial for NPM1-mutant acute myeloid leukemia, while Tipifarnib has received Breakthrough Therapy Designation in treating HRAS-mutant head and neck squamous cell carcinoma. To join the call, U.S. callers can dial 1-877-407-4018.

Positive

• Ongoing trials for Ziftomenib and Tipifarnib could enhance future revenue.
• Tipifarnib has received Breakthrough Therapy Designation, which may accelerate its market entry.

Negative

• The company is in the clinical stage, indicating a lack of immediate revenue generation.
• -

SAN DIEGO, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report fourth quarter and full year 2022 financial results after U.S. financial markets close on Thursday, February 23, 2023. Kura’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update. 

To participate in the teleconference, domestic callers should dial 1-877-407-4018 and international callers should dial 1-201-689-8471. A live webcast of the call can be accessed using this weblink: https://viavid.webcasts.com/starthere.jsp?ei=1595273&tp_key=5fdc524c8f. A replay of the webcast will be available online from the investor relations section of the company website at www.kuraoncology.com.

About Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways. Ziftomenib, a potent and selective menin inhibitor, is currently in a registration-directed trial for patients with NPM1-mutant acute myeloid leukemia. Tipifarnib, a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI), has received Breakthrough Therapy Designation for the treatment of patients with HRAS-mutant HNSCC. Kura is conducting a Phase 1/2 trial (KURRENT-HN) of tipifarnib in combination with the PI3Kα inhibitor alpelisib to address larger genetic subsets of HNSCC patients. Kura intends to perform initial clinical evaluation with tipifarnib while in parallel advancing KO-2806, the Company’s next-generation FTI, through a Phase 1 first-in-human study. For additional information, please visit Kura’s website at www.kuraoncology.com.

Contacts

Investors: 
Pete De Spain 
Senior Vice President, Investor Relations & 
Corporate Communications 
(858) 500-8803 
pete@kuraoncology.com 

Media:
Alexandra Weingarten
Senior Manager, Corporate Communications
(858) 500-8822
alexandra@kuraoncology.com

FAQ

When will Kura Oncology report its 2022 financial results?

Kura Oncology will report its financial results on February 23, 2023.

What is the significance of Kura's Breakthrough Therapy Designation?

The Breakthrough Therapy Designation for Tipifarnib may expedite its development and approval process.

How are the clinical trials of Kura's drug candidates progressing?

Ziftomenib is in a registration-directed trial, and Tipifarnib is in a Phase 1/2 trial.

What time is Kura's conference call scheduled for?

The conference call is scheduled for 4:30 p.m. ET on February 23, 2023.